Your search for osteoporosis returned 1 results

Exemestane, an aromatase inhibitor, can be considered a new option for primary prevention of breast cancer in postmenopausal women, results of a randomized, placebo-controlled trial reported upon during the American Society of Clinical Oncology’s 2011 Annual Meeting and published online in The New England Journal of Medicine have found.